NKTR Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-26 | 2022 | Jillian B. Thomsen Former Chief Financial Officer and Chief Accounting Officer | 522,200 | 0 | 1,629,478 | 198,000 | 22,645 | 4,558,317 |
| 2024-04-26 | 2023 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 0 | 1,030,361 | 93,465 | 3,135,576 |
| 2024-04-26 | 2022 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 4,032,255 | 650,754 | 98,821 | 11,275,830 |
| 2024-04-26 | 2021 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 5,691,794 | 1,000,350 | 81,980 | 11,153,616 |
| 2024-04-26 | 2023 | Sandra Gardiner Interim Chief Financial Officer | 0 | 0 | 0 | 0 | 376,300 | 376,300 |
| 2024-04-26 | 2023 | Mark A. Wilson Chief Legal Officer | 540,000 | 0 | 0 | 307,800 | 20,878 | 1,100,468 |
| 2024-04-26 | 2022 | Mark A. Wilson Chief Legal Officer | 527,500 | 0 | 1,629,478 | 194,400 | 28,093 | 4,565,465 |
| 2024-04-26 | 2021 | Mark A. Wilson Chief Legal Officer | 500,000 | 0 | 1,707,078 | 287,500 | 10,763 | 3,503,661 |
| 2024-04-26 | 2023 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 0 | 400,989 | 490,585 | 1,773,364 |
| 2024-04-26 | 2022 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 1,325,673 | 253,256 | 289,625 | 4,350,480 |
| 2024-04-26 | 2021 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,391,094 | 471,270 | 8,385 | 4,951,247 |
| 2024-04-26 | 2023 | Jillian B. Thomsen Former Chief Financial Officer and Chief Accounting Officer | 355,760 | 0 | 0 | 0 | 883,999 | 1,239,759 |
| 2023-04-28 | 2022 | John Northcott Former Chief Commercial Officer | 441,662 | 0 | 0 | 0 | 923,019 | 1,364,681 |
| 2023-04-28 | 2021 | John Northcott Former Chief Commercial Officer | 675,000 | 0 | 1,707,078 | 388,125 | 7,950 | 3,776,473 |
| 2023-04-28 | 2020 | John Northcott Former Chief Commercial Officer | 675,000 | 0 | 1,604,292 | 364,500 | 117,884 | 3,832,798 |
| 2023-04-28 | 2022 | Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer | 576,733 | 0 | 0 | 0 | 10,972 | 587,705 |
| 2023-04-28 | 2021 | Mark A. Wilson Chief Legal Officer | 500,000 | 0 | 1,707,078 | 287,500 | 10,763 | 3,503,661 |
| 2023-04-28 | 2022 | Mark A. Wilson Chief Legal Officer | 527,500 | 0 | 1,629,478 | 194,400 | 28,093 | 4,565,465 |
| 2023-04-28 | 2022 | Jillian B. Thomsen Chief Financial Officer and Chief Accounting Officer | 522,200 | 0 | 1,629,478 | 198,000 | 22,645 | 4,558,317 |
| 2023-04-28 | 2020 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 4,996,266 | 1,092,000 | 95,775 | 11,241,149 |
| 2023-04-28 | 2021 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 5,691,794 | 1,000,350 | 81,980 | 11,153,616 |
| 2023-04-28 | 2022 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 4,032,225 | 650,754 | 98,821 | 11,275,830 |
| 2023-04-28 | 2022 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 1,325,673 | 253,256 | 289,625 | 4,350,480 |
| 2023-04-28 | 2021 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,391,094 | 471,270 | 8,385 | 4,951,247 |
| 2023-04-28 | 2020 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,247,676 | 500,000 | 9,149 | 4,941,497 |
| 2023-04-28 | 2021 | Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,391,094 | 679,650 | 23,314 | 5,279,556 |
| 2023-04-28 | 2020 | Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,247,676 | 721,000 | 27,574 | 5,285,922 |
| 2023-04-28 | 2020 | Mark A. Wilson Chief Legal Officer | 500,000 | 0 | 1,604,292 | 270,000 | 10,492 | 3,455,906 |
| 2022-04-29 | 2021 | Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer | 683,000 | 0 | 2,391,094 | 471,270 | 8,385 | 4,951,247 |
| 2022-04-29 | 2019 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 683,325 | 0 | 3,131,971 | 0 | 12,498 | 7,488,841 |
| 2022-04-29 | 2021 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,391,094 | 679,650 | 23,314 | 5,279,556 |
| 2022-04-29 | 2019 | Howard W. Robin President and Chief Executive Officer | 1,017,400 | 0 | 4,100,860 | 0 | 168,925 | 9,939,250 |
| 2022-04-29 | 2020 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 4,996,266 | 1,092,000 | 95,775 | 11,241,149 |
| 2022-04-29 | 2021 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 5,691,794 | 1,000,350 | 81,980 | 11,153,616 |
| 2022-04-29 | 2020 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,247,676 | 721,000 | 27,574 | 5,285,922 |
| 2022-04-29 | 2021 | John Northcott Senior Vice President and Chief Commercial Officer | 675,000 | 0 | 1,707,078 | 388,125 | 7,950 | 3,776,473 |
| 2022-04-29 | 2020 | John Northcott Senior Vice President and Chief Commercial Officer | 675,000 | 0 | 1,604,292 | 364,500 | 117,884 | 3,832,798 |
| 2022-04-29 | 2019 | John Northcott Senior Vice President and Chief Commercial Officer | 56,250 | 200,000 | 3,895,980 | 0 | 23,313 | 6,365,023 |
| 2022-04-29 | 2021 | Mark A. Wilson Senior Vice President and General Counsel | 500,000 | 0 | 1,707,078 | 287,500 | 10,763 | 3,503,661 |
| 2022-04-29 | 2019 | Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer | 582,000 | 0 | 3,131,971 | 0 | 8,120 | 7,274,097 |
| 2022-04-29 | 2020 | Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer | 683,000 | 0 | 2,247,676 | 500,000 | 9,149 | 4,941,497 |
| 2022-04-29 | 2020 | Mark A. Wilson Senior Vice President and General Counsel | 500,000 | 0 | 1,604,292 | 270,000 | 10,492 | 3,455,906 |
| 2021-04-30 | 2018 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 631,696 | 0 | 2,099,320 | 631,600 | 11,930 | 5,733,928 |
| 2021-04-30 | 2020 | Mark A. Wilson | 500,000 | 0 | 1,604,292 | 270,000 | 10,492 | 3,455,906 |
| 2021-04-30 | 2020 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,247,676 | 500,000 | 9,149 | 4,941,497 |
| 2021-04-30 | 2019 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 582,000 | 0 | 3,131,971 | 0 | 8,120 | 7,274,153 |
| 2021-04-30 | 2020 | Howard W. Robin President and Chief Executive Officer | 1,053,400 | 0 | 4,996,266 | 1,092,000 | 95,775 | 11,241,549 |
| 2021-04-30 | 2019 | Howard W. Robin President and Chief Executive Officer | 1,017,400 | 0 | 4,100,860 | 0 | 168,925 | 9,939,250 |
| 2021-04-30 | 2018 | Howard W. Robin President and Chief Executive Officer | 968,921 | 0 | 4,998,206 | 1,647,100 | 98,184 | 13,330,667 |
| 2021-04-30 | 2020 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,247,676 | 721,000 | 27,574 | 5,285,922 |
| 2021-04-30 | 2019 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 683,325 | 0 | 3,131,971 | 0 | 12,498 | 7,488,841 |
| 2021-04-30 | 2020 | John Northcott Senior Vice President and Chief Commercial Officer | 675,000 | 0 | 1,604,292 | 364,500 | 117,884 | 3,832,798 |
| 2021-04-30 | 2019 | John Northcott Senior Vice President and Chief Commercial Officer | 56,250 | 200,000 | 3,895,980 | 0 | 23,313 | 6,355,023 |
| 2020-04-29 | 2019 | Howard W. Robin President and Chief Executive Officer | 1,017,400 | 0 | 4,100,860 | 0 | 168,925 | 9,939,250 |
| 2020-04-29 | 2018 | Howard W. Robin President and Chief Executive Officer | 968,921 | 0 | 4,998,206 | 1,647,100 | 98,184 | 13,330,667 |
| 2020-04-29 | 2017 | Howard W. Robin President and Chief Executive Officer | 940,700 | 0 | 6,884,888 | 1,599,190 | 127,975 | 18,097,411 |
| 2020-04-29 | 2019 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 683,325 | 0 | 3,131,971 | 0 | 12,498 | 7,488,841 |
| 2020-04-29 | 2019 | John Northcott | 56,250 | 200,000 | 3,895,980 | 0 | 13,313 | 6,355,023 |
| 2020-04-29 | 2019 | Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer | 457,000 | 0 | 649,340 | 0 | 13,787 | 1,916,084 |
| 2020-04-29 | 2018 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 631,696 | 0 | 2,099,320 | 631,600 | 11,930 | 5,733,928 |
| 2020-04-29 | 2018 | Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer | 435,000 | 0 | 4,461,658 | 424,100 | 13,347 | 6,233,595 |
| 2020-04-29 | 2019 | Jonathan Zalevsky, Ph.D. | 582,000 | 0 | 3,131,971 | 0 | 8,120 | 7,274,153 |
| 2020-04-29 | 2017 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 607,400 | 0 | 2,958,794 | 531,475 | 10,338 | 7,780,091 |
| 2019-04-30 | 2018 | Jillian B. Thomsen | 435,000 | 0 | 4,461,657 | 424,100 | 13,347 | 6,233,595 |
| 2019-04-30 | 2018 | Howard W. Robin President and Chief Executive Officer | 968,921 | 0 | 4,998,206 | 1,647,100 | 98,184 | 13,330,667 |
| 2019-04-30 | 2017 | Howard W. Robin President and Chief Executive Officer | 940,700 | 0 | 6,884,888 | 1,599,190 | 127,975 | 18,097,411 |
| 2019-04-30 | 2016 | Howard W. Robin President and Chief Executive Officer | 920,000 | 0 | 1,346,390 | 897,000 | 15,103 | 4,764,143 |
| 2019-04-30 | 2018 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 631,696 | 0 | 2,099,320 | 631,600 | 11,930 | 5,733,928 |
| 2019-04-30 | 2017 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 607,400 | 0 | 2,958,794 | 531,475 | 10,338 | 7,780,091 |
| 2019-04-30 | 2016 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 582,167 | 0 | 489,596 | 356,400 | 8,653 | 2,739,936 |
| 2019-04-30 | 2018 | Stephen K. Doberstein, Ph.D. Chief Research and Development Officer | 600,000 | 0 | 1,748,824 | 480,000 | 17,556 | 4,811,856 |
| 2019-04-30 | 2017 | Stephen K. Doberstein, Ph.D. Chief Research and Development Officer | 529,084 | 0 | 2,958,794 | 525,000 | 13,988 | 7,698,950 |
| 2019-04-30 | 2016 | Stephen K. Doberstein, Ph.D. Chief Research and Development Officer | 508,200 | 0 | 428,396 | 266,805 | 12,806 | 1,720,733 |
| 2019-04-30 | 2018 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and | 489,417 | 0 | 1,350,866 | 464,900 | 17,513 | 3,839,442 |
| 2019-04-30 | 2017 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and | 471,500 | 0 | 1,706,998 | 353,625 | 15,394 | 4,666,027 |
| 2019-04-30 | 2016 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and | 447,800 | 0 | 367,197 | 279,875 | 14,454 | 1,541,776 |
| 2018-04-30 | 2017 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer | 529,084 | 0 | 2,958,794 | 525,000 | 13,988 | 7,698,950 |
| 2018-04-30 | 2016 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 582,167 | 0 | 489,596 | 356,400 | 8,653 | 2,739,936 |
| 2018-04-30 | 2017 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 607,400 | 0 | 2,958,794 | 531,475 | 10,338 | 7,780,091 |
| 2018-04-30 | 2015 | Howard W. Robin President and Chief Executive Officer | 892,620 | 0 | 2,099,236 | 625,000 | 12,156 | 4,445,988 |
| 2018-04-30 | 2016 | Howard W. Robin President and Chief Executive Officer | 920,000 | 0 | 1,346,390 | 897,000 | 15,103 | 4,764,143 |
| 2018-04-30 | 2015 | John Nicholson Senior Vice President and Chief Operating Officer | 563,100 | 0 | 808,594 | 267,500 | 12,661 | 1,971,383 |
| 2018-04-30 | 2016 | John Nicholson Senior Vice President and Chief Operating Officer | 599,833 | 0 | 489,596 | 367,200 | 14,995 | 2,774,744 |
| 2018-04-30 | 2017 | John Nicholson Senior Vice President and Chief Operating Officer | 625,800 | 0 | 2,958,794 | 547,575 | 26,907 | 7,831,160 |
| 2018-04-30 | 2015 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and | 430,600 | 0 | 808,595 | 204,500 | 14,815 | 1,778,038 |
| 2018-04-30 | 2016 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and | 447,800 | 0 | 367,197 | 279,875 | 14,454 | 1,541,776 |
| 2018-04-30 | 2017 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and | 471,500 | 0 | 1,706,998 | 353,625 | 15,394 | 4,666,027 |
| 2018-04-30 | 2015 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer | 495,800 | 0 | 326,548 | 198,300 | 13,054 | 1,161,287 |
| 2018-04-30 | 2016 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer | 508,200 | 0 | 428,396 | 266,805 | 12,806 | 1,720,733 |
| 2018-04-30 | 2017 | Howard W. Robin President and Chief Executive Officer | 940,700 | 0 | 6,884,888 | 1,599,190 | 127,975 | 18,097,411 |
| 2018-04-30 | 2015 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 546,500 | 0 | 808,594 | 259,600 | 9,562 | 1,943,784 |
| 2017-05-01 | 2015 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 546,500 | 0 | 808,594 | 259,600 | 9,562 | 1,943,784 |
| 2017-05-01 | 2016 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 582,167 | 0 | 489,596 | 356,400 | 8,653 | 2,739,936 |
| 2017-05-01 | 2016 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 447,800 | 0 | 367,197 | 279,875 | 14,454 | 1,541,776 |
| 2017-05-01 | 2014 | Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer | 372,728 | 0 | 0 | 227,500 | 2,133 | 4,213,251 |
| 2017-05-01 | 2015 | Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer | 621,000 | 0 | 466,498 | 279,500 | 6,657 | 1,555,205 |
| 2017-05-01 | 2016 | Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer | 639,600 | 0 | 489,596 | 335,790 | 9,837 | 2,617,883 |
| 2017-05-01 | 2014 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer | 477,583 | 0 | 0 | 311,350 | 11,804 | 2,139,128 |
| 2017-05-01 | 2014 | Howard W. Robin President and Chief Executive Officer | 860,004 | 0 | 0 | 1,131,945 | 18,278 | 8,032,982 |
| 2017-05-01 | 2015 | Howard W. Robin President and Chief Executive Officer | 892,620 | 0 | 2,099,236 | 625,000 | 12,156 | 4,445,988 |
| 2017-05-01 | 2016 | Howard W. Robin President and Chief Executive Officer | 920,000 | 0 | 1,346,390 | 897,000 | 15,103 | 4,764,143 |
| 2017-05-01 | 2014 | John Nicholson Senior Vice President and Chief Operating Officer | 542,458 | 0 | 0 | 408,000 | 12,854 | 3,305,495 |
| 2017-05-01 | 2015 | John Nicholson Senior Vice President and Chief Operating Officer | 563,100 | 0 | 808,594 | 267,500 | 12,661 | 1,971,383 |
| 2017-05-01 | 2016 | John Nicholson Senior Vice President and Chief Operating Officer | 599,833 | 0 | 489,596 | 367,200 | 14,995 | 2,774,744 |
| 2017-05-01 | 2015 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 430,600 | 0 | 808,595 | 204,500 | 14,815 | 1,778,038 |
| 2017-05-01 | 2015 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer | 495,800 | 0 | 326,548 | 198,300 | 13,054 | 1,161,287 |
| 2017-05-01 | 2016 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer | 508,200 | 0 | 428,396 | 266,805 | 12,806 | 1,720,733 |
| 2017-05-01 | 2014 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 526,125 | 0 | 0 | 396,000 | 8,354 | 3,242,858 |
| 2016-04-29 | 2014 | John Nicholson Senior Vice President and Chief Financial Officer | 542,458 | 0 | 0 | 408,000 | 12,854 | 3,305,495 |
| 2016-04-29 | 2013 | John Nicholson Senior Vice President and Chief Financial Officer | 524,264 | 0 | 0 | 276,000 | 12,112 | 1,662,210 |
| 2016-04-29 | 2015 | Ivan P. Gergel Senior Vice President and | 621,000 | 0 | 466,498 | 279,500 | 6,657 | 1,555,205 |
| 2016-04-29 | 2014 | Ivan P. Gergel Senior Vice President and | 372,728 | 0 | 0 | 227,500 | 2,133 | 4,213,251 |
| 2016-04-29 | 2015 | Maninder Hora | 430,600 | 0 | 808,594 | 204,500 | 14,815 | 1,778,037 |
| 2016-04-29 | 2015 | Gil M. Labrucherie Senior Vice President and General Counsel | 546,500 | 0 | 808,594 | 259,600 | 9,562 | 1,943,784 |
| 2016-04-29 | 2014 | Gil M. Labrucherie Senior Vice President and General Counsel | 526,125 | 0 | 0 | 396,000 | 8,354 | 3,242,858 |
| 2016-04-29 | 2013 | Gil M. Labrucherie Senior Vice President and General Counsel | 504,195 | 0 | 0 | 278,000 | 7,238 | 1,478,488 |
| 2016-04-29 | 2015 | Howard W. Robin President and Chief Executive Officer | 892,620 | 0 | 2,099,236 | 625,000 | 12,156 | 4,445,988 |
| 2016-04-29 | 2014 | Howard W. Robin President and Chief Executive Officer | 860,004 | 0 | 0 | 1,131,945 | 18,278 | 8,032,982 |
| 2016-04-29 | 2013 | Howard W. Robin President and Chief Executive Officer | 831,247 | 0 | 0 | 656,200 | 15,040 | 3,569,652 |
| 2016-04-29 | 2015 | John Nicholson Senior Vice President and Chief Financial Officer | 563,100 | 0 | 808,594 | 267,500 | 12,661 | 1,971,383 |
| 2015-04-30 | 2014 | Ivan P. Gergel | 372,728 | 0 | 0 | 227,500 | 2,133 | 4,213,251 |
| 2015-04-30 | 2012 | Howard W. Robin President and Chief Executive Officer | 807,196 | 500 | 0 | 910,125 | 14,351 | 3,242,332 |
| 2015-04-30 | 2013 | Howard W. Robin President and Chief Executive Officer | 831,247 | 0 | 0 | 656,200 | 15,039 | 3,569,652 |
| 2015-04-30 | 2014 | Howard W. Robin President and Chief Executive Officer | 860,004 | 0 | 0 | 1,131,945 | 18,279 | 8,032,982 |
| 2015-04-30 | 2014 | Gil M. Labrucherie Senior Vice President and General Counsel | 526,125 | 0 | 0 | 396,000 | 8,354 | 3,242,858 |
| 2015-04-30 | 2013 | Gil M. Labrucherie Senior Vice President and General Counsel | 504,195 | 0 | 0 | 278,000 | 7,238 | 1,478,488 |
| 2015-04-30 | 2012 | Gil M. Labrucherie Senior Vice President and General Counsel | 488,270 | 0 | 0 | 330,000 | 6,503 | 1,391,083 |
| 2015-04-30 | 2014 | John Nicholson Senior Vice President and Chief Financial Officer | 542,458 | 0 | 0 | 408,000 | 12,854 | 3,305,495 |
| 2015-04-30 | 2013 | John Nicholson Senior Vice President and Chief Financial Officer | 524,264 | 0 | 0 | 276,000 | 12,112 | 1,662,210 |
| 2015-04-30 | 2012 | John Nicholson Senior Vice President and Chief Financial Officer | 509,529 | 500 | 0 | 357,000 | 12,225 | 1,256,794 |
| 2015-04-30 | 2014 | Stephen K. Doberstein Senior Vice President and Chief Scientific Officer | 477,583 | 0 | 0 | 311,350 | 11,804 | 2,139,128 |
| 2015-04-30 | 2013 | Stephen K. Doberstein Senior Vice President and Chief Scientific Officer | 459,722 | 0 | 0 | 231,000 | 9,513 | 1,159,605 |
| 2015-04-30 | 2012 | Stephen K. Doberstein Senior Vice President and Chief Scientific Officer | 433,605 | 0 | 0 | 260,000 | 9,613 | 1,080,758 |
| 2014-04-30 | 2013 | Name and Position | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-04-30 | 2012 | Howard W. Robin President and Chief Executive Officer | 807,196 | 500 | 0 | 910,125 | 18,334 | 3,246,314 |
| 2013-04-30 | 2011 | Howard W. Robin President and Chief Executive Officer | 785,131 | 0 | 0 | 650,000 | 14,973 | 3,182,634 |
| 2013-04-30 | 2010 | Howard W. Robin President and Chief Executive Officer | 758,581 | 0 | 0 | 700,000 | 14,973 | 4,492,504 |
| 2012-04-30 | 2011 | Howard W. Robin President and Chief Executive Officer | 785,131 | 0 | 0 | 650,000 | 14,973 | 3,182,634 |
| 2012-04-30 | 2009 | Howard W. Robin President and Chief Executive Officer | 730,417 | 0 | 0 | 1,000,000 | 14,973 | 3,003,133 |
| 2012-04-30 | 2010 | Howard W. Robin President and Chief Executive Officer | 758,581 | 0 | 0 | 700,000 | 14,973 | 4,492,504 |
| 2011-04-29 | 2010 | Stephen K. Doberstein Ph.D. Senior Vice President and Chief Scientific Officer | 395,455 | 150,000 | 0 | 240,000 | 7,818 | 3,533,340 |
| 2011-04-29 | 2010 | Gil M. Labrucherie Senior Vice President and General Counsel | 434,250 | 500 | 0 | 294,300 | 13,272 | 1,466,871 |
| 2011-04-29 | 2009 | Gil M. Labrucherie Senior Vice President and General Counsel | 412,242 | 0 | 0 | 363,500 | 13,063 | 1,795,052 |
| 2011-04-29 | 2008 | Gil M. Labrucherie Senior Vice President and General Counsel | 380,098 | 100,000 | 0 | 381,900 | 9,409 | 1,080,161 |
| 2011-04-29 | 2008 | Howard W. Robin President and Chief Executive Officer | 680,000 | 0 | 0 | 618,800 | 14,586 | 2,506,266 |
| 2011-04-29 | 2009 | Howard W. Robin President and Chief Executive Officer | 730,417 | 0 | 0 | 1,000,000 | 14,973 | 3,003,133 |
| 2011-04-29 | 2010 | Howard W. Robin President and Chief Executive Officer | 758,581 | 0 | 0 | 700,000 | 14,973 | 4,492,504 |
| 2011-04-29 | 2010 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 478,417 | 0 | 0 | 288,000 | 15,330 | 1,506,295 |
| 2011-04-29 | 2009 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 459,594 | 0 | 0 | 403,500 | 51,198 | 1,835,959 |
| 2011-04-29 | 2008 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 442,531 | 0 | 0 | 388,610 | 108,600 | 1,193,228 |
| 2011-04-29 | 2010 | Rinko Ghosh Senior Vice President and Chief Business Officer | 397,739 | 0 | 0 | 276,750 | 8,009 | 2,215,826 |
| 2010-04-30 | 2009 | Name and Position | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-29 | 2008 | Gil M. Labrucherie | 380,098 | 100,000 | 10,668 | 381,900 | 9,409 | 1,175,975 |
| 2009-04-29 | 2008 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 438,739 | 250,000 | 0 | 0 | 653,666 | 1,949,881 |
| 2009-04-29 | 2007 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 372,638 | 0 | 0 | 282,800 | 2,886 | 933,064 |
| 2009-04-29 | 2006 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 321,332 | 0 | 35,911 | 114,804 | 582 | 649,598 |
| 2009-04-29 | 2007 | Howard W. Robin President and Chief Executive Officer | 654,243 | 0 | 0 | 601,800 | 4,083 | 2,227,770 |
| 2009-04-29 | 2008 | Howard W. Robin President and Chief Executive Officer | 680,000 | 0 | 0 | 618,800 | 14,586 | 2,149,092 |
| 2009-04-29 | 2008 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 442,531 | 0 | 18,190 | 388,610 | 108,600 | 1,309,797 |
| 2009-04-29 | 2008 | Bharatt M. Chowrira | 295,076 | 80,485 | 0 | 427,500 | 4,386 | 951,161 |
| 2009-04-29 | 2007 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 104,641 | 0 | 1,055 | 82,300 | 31,185 | 273,470 |
| 2008-04-29 | 2007 | Louis Drapeau Former Senior Vice President, Finance and Chief Financial Officer | 252,399 | 0 | 0 | 64,772 | 404,367 | 881,418 |
| 2008-04-29 | 2007 | Timothy Harkness Former Senior Vice President, Finance and Chief Financial Officer | 141,094 | 0 | 6,581 | 0 | 739,445 | 937,166 |
| 2008-04-29 | 2006 | Robert B. Chess Former Acting President and Chief Executive Officer | 418,459 | 0 | 716,224 | 262,718 | 8,040 | 2,417,150 |
| 2008-04-29 | 2006 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 321,332 | 0 | 35,911 | 114,804 | 582 | 649,598 |
| 2008-04-29 | 2007 | Robert B. Chess Former Acting President and Chief Executive Officer | 100,000 | 317,000 | 339,753 | 0 | 8,734 | 1,468,751 |
| 2008-04-29 | 2007 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 372,638 | 0 | 0 | 282,800 | 2,886 | 933,064 |
| 2008-04-29 | 2006 | Louis Drapeau Former Senior Vice President, Finance and Chief Financial Officer | 336,589 | 0 | 0 | 119,968 | 11,355 | 669,371 |
| 2008-04-29 | 2007 | David Johnston Former Senior Vice President Research and Development | 390,831 | 42,028 | 18,266 | 71,248 | 528,870 | 1,179,043 |
| 2008-04-29 | 2006 | David Johnston Former Senior Vice President Research and Development | 335,910 | 0 | 71,157 | 119,574 | 9,759 | 701,947 |
| 2008-04-29 | 2007 | Howard W. Robin President and Chief Executive Officer | 654,243 | 0 | 0 | 601,800 | 4,083 | 2,227,770 |
| 2008-04-29 | 2007 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 104,641 | 0 | 1,055 | 82,300 | 31,185 | 273,470 |
| 2008-04-29 | 2007 | Hoyoung Huh M.D., Ph.D. Chief Operating Officer and Head of the PEGylation Business Unit | 451,153 | 20,000 | 0 | 344,000 | 9,182 | 1,231,782 |
| 2008-04-29 | 2007 | John S. Patton, Ph.D. Chief Research Fellow | 303,214 | 86,256 | 70,875 | 164,500 | 33,833 | 833,217 |
| 2008-04-29 | 2006 | John S. Patton, Ph.D. Chief Research Fellow | 286,534 | 0 | 292,289 | 131,060 | 9,071 | 822,366 |
| 2007-04-25 | 2006 | David Johnston Senior Vice President Research and Development | 335,910 | 0 | 71,157 | 119,574 | 9,759 | 701,947 |
| 2007-04-25 | 2006 | Robert B. Chess Acting President and Chief Executive Officer | 418,459 | 0 | 716,224 | 262,718 | 8,040 | 2,417,150 |
| 2007-04-25 | 2006 | John S. Patton, Ph.D. Chief Scientific Officer | 286,534 | 0 | 292,289 | 131,060 | 9,071 | 822,397 |
| 2007-04-25 | 2006 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 321,332 | 0 | 35,911 | 114,804 | 582 | 649,598 |
| 2007-04-25 | 2006 | Louis Drapeau Senior Vice President, Finance and Chief Financial Officer | 336,589 | 0 | 0 | 119,968 | 11,355 | 669,372 |
| 2007-04-25 | 2006 | Ajit S. Gill President and Chief Executive Officer | 285,371 | 0 | 1,388,172 | 148,994 | 1,700,877 | 12,312,868 |
| 2007-04-25 | 2006 | Ajay Bansal Senior Vice President of Finance and Chief Financial Officer | 74,142 | 0 | 349,059 | 25,048 | 457,258 | 1,252,073 |
| 2006-04-18 | 2005 | David Johnston Senior Vice President Research & Development | 314,246 | 129,253 | 184,500 | 0 | 9,261 | 637,260 |
| 2006-04-18 | 2003 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 248,908 | 112,822 | 0 | 0 | 8,270 | 370,000 |
| 2006-04-18 | 2004 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 261,354 | 127,105 | 476,250 | 0 | 6,740 | 871,449 |
| 2006-04-18 | 2005 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 274,583 | 142,735 | 184,500 | 0 | 7,793 | 609,611 |
| 2006-04-18 | 2003 | Ajay Bansal Chief Financial Officer | 235,308 | 170,067 | 0 | 0 | 4,726 | 410,101 |
| 2006-04-18 | 2004 | Ajay Bansal Chief Financial Officer | 288,650 | 105,188 | 476,250 | 0 | 6,995 | 877,083 |
| 2006-04-18 | 2005 | Ajay Bansal Chief Financial Officer | 307,824 | 122,832 | 185,400 | 0 | 3,824 | 619,880 |
| 2006-04-18 | 2003 | Robert B. Chess Executive Chairman | 183,641 | 115,337 | 0 | 0 | 6,559 | 305,537 |
| 2006-04-18 | 2004 | Robert B. Chess Executive Chairman | 167,019 | 93,603 | 325,820 | 0 | 7,435 | 593,877 |
| 2006-04-18 | 2005 | Robert B. Chess Executive Chairman | 135,805 | 80,892 | 0 | 0 | 8,425 | 225,122 |
| 2006-04-18 | 2003 | Ajit S. Gill Chief Executive Officer, President and Director | 474,461 | 250,903 | 0 | 0 | 9,968 | 735,332 |
| 2006-04-18 | 2004 | Ajit S. Gill Chief Executive Officer, President and Director | 498,049 | 272,289 | 977,500 | 0 | 10,278 | 1,758,116 |
| 2006-04-18 | 2005 | Ajit S. Gill Chief Executive Officer, President and Director | 510,833 | 262,786 | 904,000 | 0 | 11,113 | 1,688,732 |
| 2006-04-18 | 2003 | David Johnston Senior Vice President Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2006-04-18 | 2004 | David Johnston Senior Vice President Research & Development | 300,000 | 83,500 | 0 | 0 | 7,542 | 391,042 |
| 2005-04-14 | 2004 | Ajay Bansal Chief Financial Officer | 288,650 | 105,188 | 476,250 | 0 | 6,995 | 877,083 |
| 2005-04-14 | 2003 | Ajay Bansal Chief Financial Officer | 235,308 | 170,067 | 0 | 0 | 4,726 | 410,101 |
| 2005-04-14 | 2004 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 261,354 | 127,105 | 476,250 | 0 | 6,740 | 871,449 |
| 2005-04-14 | 2002 | Ajay Bansal Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-14 | 2002 | David Johnston Senior Vice President Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-14 | 2003 | David Johnston Senior Vice President Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-14 | 2002 | J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation | 324,000 | 186,977 | 0 | 0 | 7,480 | 518,457 |
| 2005-04-14 | 2003 | J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation | 321,000 | 110,662 | 0 | 0 | 7,980 | 439,642 |
| 2005-04-14 | 2004 | J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation | 342,405 | 153,629 | 0 | 0 | 11,094 | 507,128 |
| 2005-04-14 | 2002 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 236,833 | 90,921 | 0 | 0 | 7,871 | 335,625 |
| 2005-04-14 | 2003 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 248,908 | 112,822 | 0 | 0 | 8,270 | 370,000 |
| 2005-04-14 | 2004 | David Johnston Senior Vice President Research & Development | 300,000 | 83,500 | 0 | 0 | 7,542 | 391,042 |
| 2005-04-14 | 2004 | Ajit S. Gill Chief Executive Officer, President and Director | 498,049 | 272,289 | 977,500 | 0 | 10,278 | 1,758,116 |
| 2005-04-14 | 2003 | Ajit S. Gill Chief Executive Officer, President and Director | 474,461 | 250,903 | 0 | 0 | 9,968 | 735,332 |
| 2005-04-14 | 2002 | Ajit S. Gill Chief Executive Officer, President and Director | 451,206 | 201,442 | 0 | 0 | 7,173 | 659,821 |
| 2005-04-14 | 2004 | Robert B. Chess Executive Chairman | 167,019 | 93,603 | 325,820 | 0 | 7,435 | 593,877 |
| 2005-04-14 | 2003 | Robert B. Chess Executive Chairman | 183,641 | 115,337 | 0 | 0 | 6,559 | 305,537 |
| 2005-04-14 | 2002 | Robert B. Chess Executive Chairman | 251,722 | 117,183 | 0 | 0 | 6,628 | 375,533 |
| 2004-04-29 | 2003 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 248,908 | 112,822 | 0 | 0 | 8,270 | 370,000 |
| 2004-04-29 | 2001 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 156,000 | 0 | 0 | 0 | 450 | 156,450 |
| 2004-04-29 | 2002 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 324,000 | 186,977 | 0 | 0 | 7,480 | 518,457 |
| 2004-04-29 | 2003 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 321,000 | 110,662 | 0 | 0 | 7,980 | 439,642 |
| 2004-04-29 | 2001 | Ajay Bansal Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2004-04-29 | 2002 | Ajay Bansal Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2004-04-29 | 2003 | Ajay Bansal Chief Financial Officer | 235,308 | 170,067 | 0 | 0 | 4,726 | 410,101 |
| 2004-04-29 | 2001 | Robert B. Chess Executive Chairman | 254,138 | 121,270 | 0 | 0 | 5,520 | 380,928 |
| 2004-04-29 | 2002 | Robert B. Chess Executive Chairman | 251,722 | 117,183 | 0 | 0 | 6,628 | 375,533 |
| 2004-04-29 | 2003 | Robert B. Chess Executive Chairman | 183,641 | 115,337 | 0 | 0 | 6,559 | 305,537 |
| 2004-04-29 | 2001 | Ajit S. Gill Chief Executive Officer, President and Director | 422,100 | 201,135 | 0 | 0 | 6,066 | 629,301 |
| 2004-04-29 | 2002 | Ajit S. Gill Chief Executive Officer, President and Director | 451,206 | 201,442 | 0 | 0 | 7,173 | 659,821 |
| 2004-04-29 | 2003 | Ajit S. Gill Chief Executive Officer, President and Director | 474,461 | 250,903 | 0 | 0 | 9,968 | 735,332 |
| 2004-04-29 | 2001 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 222,833 | 90,125 | 0 | 0 | 6,906 | 319,864 |
| 2004-04-29 | 2002 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 236,833 | 90,921 | 0 | 0 | 7,871 | 335,625 |
| 2003-04-28 | 2000 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 209,271 | 92,369 | 0 | 0 | 1,659 | 303,299 |
| 2003-04-28 | 2002 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 236,833 | 90,921 | 0 | 0 | 7,871 | 335,625 |
| 2003-04-28 | 2000 | Arnold J. Repta, Ph.D. Vice President, Research and Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2003-04-28 | 2001 | Arnold J. Repta, Ph.D. Vice President, Research and Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2003-04-28 | 2002 | Arnold J. Repta, Ph.D. Vice President, Research and Development | 373,060 | 71,458 | 0 | 0 | 9,095 | 453,613 |
| 2003-04-28 | 2000 | Robert B. Chess Executive Chairman | 251,250 | 668,945 | 0 | 0 | 5,520 | 925,715 |
| 2003-04-28 | 2001 | Robert B. Chess Executive Chairman | 254,138 | 121,270 | 0 | 0 | 5,520 | 380,928 |
| 2003-04-28 | 2002 | Robert B. Chess Executive Chairman | 251,722 | 117,183 | 0 | 0 | 6,628 | 375,533 |
| 2003-04-28 | 2000 | Ajit S. Gill Chief Executive Officer, President and Director | 387,788 | 746,546 | 0 | 0 | 6,066 | 1,140,400 |
| 2003-04-28 | 2001 | Ajit S. Gill Chief Executive Officer, President and Director | 422,100 | 201,135 | 0 | 0 | 6,066 | 629,301 |
| 2003-04-28 | 2002 | Ajit S. Gill Chief Executive Officer, President and Director | 451,206 | 201,442 | 0 | 0 | 7,173 | 659,821 |
| 2003-04-28 | 2000 | Douglas H. Altschuler Former Vice President, General Counsel and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| 2003-04-28 | 2001 | Douglas H. Altschuler Former Vice President, General Counsel and Secretary | 61,894 | 25,000 | 0 | 0 | 158 | 87,052 |
| 2003-04-28 | 2002 | Douglas H. Altschuler Former Vice President, General Counsel and Secretary | 307,500 | 68,402 | 0 | 0 | 6,694 | 382,596 |
| 2003-04-28 | 2000 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 0 | 0 | 0 | 0 | 0 | 0 |
| 2003-04-28 | 2001 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 156,000 | 0 | 0 | 0 | 450 | 156,450 |
| 2003-04-28 | 2002 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 324,000 | 186,977 | 0 | 0 | 7,480 | 518,457 |
| 2003-04-28 | 2001 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 222,833 | 90,125 | 0 | 0 | 6,906 | 319,864 |
| 2002-05-15 | 2000 | Douglas H. Altschuler Vice President, General Counsel and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| 2002-05-15 | 1999 | Brigid A. Makes Vice President, Finance & Administration, Chief Financial Officer and Assistant Secretary | 87,739 | 30,000 | 0 | 0 | 175 | 117,914 |
| 2002-05-15 | 2000 | Brigid A. Makes Vice President, Finance & Administration, Chief Financial Officer and Assistant Secretary | 205,750 | 70,636 | 0 | 0 | 5,730 | 282,116 |
| 2002-05-15 | 2000 | John S. Patton Founder, Chief Scientific Officer and Director | 209,271 | 92,369 | 0 | 0 | 1,659 | 303,299 |
| 2002-05-15 | 1999 | Stephen L. Hurst Vice President, Human Resources | 179,316 | 57,605 | 0 | 0 | 1,186 | 238,107 |
| 2002-05-15 | 2001 | Douglas H. Altschuler Vice President, General Counsel and Secretary | 61,894 | 25,000 | 0 | 0 | 158 | 87,052 |
| 2002-05-15 | 2001 | Brigid A. Makes Vice President, Finance & Administration, Chief Financial Officer and Assistant Secretary | 219,313 | 68,911 | 0 | 0 | 5,730 | 293,954 |
| 2002-05-15 | 1999 | John S. Patton Founder, Chief Scientific Officer and Director | 190,774 | 76,518 | 0 | 0 | 6,117 | 273,409 |
| 2002-05-15 | 2001 | John S. Patton Founder, Chief Scientific Officer and Director | 222,833 | 90,125 | 0 | 0 | 6,906 | 319,864 |
| 2002-05-15 | 1999 | Robert B. Chess Executive Chairman | 248,013 | 113,249 | 0 | 0 | 6,005 | 367,267 |
| 2002-05-15 | 2000 | Robert B. Chess Executive Chairman | 251,250 | 668,945 | 0 | 0 | 5,520 | 925,715 |
| 2002-05-15 | 2001 | Robert B. Chess Executive Chairman | 254,138 | 121,270 | 0 | 0 | 5,520 | 380,928 |
| 2002-05-15 | 1999 | Ajit S. Gill Chief Executive Officer, President and Director | 248,013 | 113,249 | 0 | 0 | 6,452 | 367,714 |
| 2002-05-15 | 2000 | Ajit S. Gill Chief Executive Officer, President and Director | 387,788 | 746,546 | 0 | 0 | 6,066 | 1,140,400 |
| 2002-05-15 | 2001 | Ajit S. Gill Chief Executive Officer, President and Director | 422,100 | 201,135 | 0 | 0 | 6,066 | 629,301 |
| 2002-05-15 | 2000 | Stephen L. Hurst Vice President, Human Resources | 171,863 | 96,044 | 0 | 0 | 3,427 | 271,334 |
| 2002-05-15 | 2001 | Stephen L. Hurst Vice President, Human Resources | 129,050 | 54,234 | 0 | 0 | 4,498 | 187,782 |
| 2002-05-15 | 1999 | Douglas H. Altschuler Vice President, General Counsel and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
